United Therapeutics (NASDAQ:UTHR) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

United Therapeutics (NASDAQ:UTHR) announced its quarterly earnings results on Wednesday. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09, RTT News reports. The business had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the company earned $4.36 EPS.

United Therapeutics Trading Up 1.5 %

UTHR opened at $323.62 on Friday. United Therapeutics has a 1-year low of $221.53 and a 1-year high of $417.82. The stock has a market capitalization of $14.45 billion, a price-to-earnings ratio of 14.21, a P/E/G ratio of 0.97 and a beta of 0.57. The business has a 50 day moving average of $360.44 and a 200-day moving average of $360.55.

Insider Activity

In related news, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the completion of the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the firm’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the completion of the transaction, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This trade represents a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 124,164 shares of company stock valued at $45,278,893. 11.90% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. LADENBURG THALM/SH SH lifted their price target on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a report on Thursday, October 31st. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.